AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%
Columbia Care Inc
Columbia Care Inc (OTC: CCHWF) is the provider of Cannabis-based health & wellness solutions.
Investment Highlights – Columbia Care Inc – Speculative Buy at USD 4.77
Key Risks
Recent Developments
On 15 June 2021, the Company stated that it had entered into an agreement to acquire Medicine Man Denver for an upfront consideration of USD 42.0 million.
On 11 June 2021, CCHWF had completed the acquisition of Green Leaf Medical worth approximately USD 240 million, well ahead of the scheduled anticipated close.
Q1 FY21 Financial Highlights (for three months ended 31 March 2021, as of 17 May 2021)
(Source: Company result)
One Year Share Price Chart
(Analysis done by Kalkine Group)
Valuation Methodology: Price/Earnings Approach (Illustrative)
Conclusion
The acquisition of Green Leaf will consolidate the leadership presence in the states of Pennsylvania, Maryland, Ohio, and Virginia. CCHWF had reaffirmed the guidance previously provided on 16 March 2021. Moreover, the Company anticipates combined revenue ranging from USD 500 million to USD 530 million for FY21. On the profitability front, the FY21 combined adjusted EBITDA would be likely to fall between USD 95 million and USD 105 million. The stock made a 52-week low and high of USD 2.40 and USD 7.89, respectively. The next important support level on the technical chart is at USD 4.38.
Based on the decent revenue guidance, bright industry outlook and valuation method used above, we have given a "Speculative Buy" stance on Columbia Care Inc at the closing market price of USD 4.77 (as of 23 June 2021), with a lower double-digit upside potential based on a 106.44x Price/NTM Earnings per share (approx.) on FY22E earnings per share (approx.).
TFF Pharmaceuticals Inc
TFF Pharmaceuticals Inc (Nasdaq: TFFP) is a biopharmaceutical entity focused on developing on a formula based on its TFF (Thin Film Freezing) technology.
Investment Highlights – SPECULATIVE BUY at USD 10.49
Key Risks
Recent News
Clinical Development: TFFP announced that its Lead Monoclonal Antibody Candidate, AUG-3387, was selected for clinical development against COVID-19.
Q1 FY21 Financial Highlights (for three months ended 31 March 2021, as of 13 May 2021)
(Source: Company website)
Share Price Chart
(Analysis done by Kalkine Group)
Valuation Methodology: EV/Sales Approach (FY21) (Illustrative)
Conclusion
TFFP has scheduled pivotal clinical trials for Voriconazole Inhalation Powder in H2 FY21 for the treatment of IPA (Invasive Pulmonary Aspergillosis), and a trial for Tacrolimus Inhalation Powder for Immunosuppression. The positive results from both trials can act as a significant growth catalyst for the Company. In March 2021, TFFP closed on an underwritten offering for nearly US$30,000,000 in gross proceeds, which boosted the Company's liquidity to pursue its growth opportunities. The stock made a 52-week High and Low of USD 21.14 and USD 5.38, respectively. On the technical chart, the next important support level is at USD 8.60.
Based on the progress achieved across the promising clinical developments, strategic partnerships, solid liquidity, and favourable valuation conducted above, we have given a "SPECULATIVE BUY" stance on TFF Pharmaceuticals Inc at the closing market price of USD 10.49 (as of 23 June 2021), with a lower double-digit upside potential based 61.85x EV/Sales (approx.) on FY21E Sales (approx.).
*All forecasted figures and Industry Information have been taken from REFINITIV.
*The reference data in this report has been partly sourced from REFINITIV.
*Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached or if the price closes below the support level (indicative stop-loss price).